Overview

A Study for Teriparatide in Severe Osteoporosis

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This observational study will evaluate the incidence of new vertebral and non vertebral fragility fractures in patients with severe osteoporosis treated with anabolic drugs. This study will also evaluate BMD, compliance to treatment, back pain and the health-related quality of life.
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Teriparatide